Geron reported $3.83M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Amgen USD 3.86B 1.28B Mar/2026
Bio Techne USD 116.71M 13.29M Mar/2026
Cassava Sciences USD -11.73M 33.44M Sep/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
Exelixis USD 258.29M 15.43M Mar/2026
Genmab DKK 186M 291M Dec/2025
Geron USD 3.83M 25.12M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025